Palvella Therapeutics
PVLA
68 hedge funds and large institutions have $68.3M invested in Palvella Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 26 reducing their positions, and 15 closing their positions.
825% more call options, than puts
Call options by funds: $222K | Put options by funds: $24K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.01% less ownership
Funds ownership: 0.64% → 0.63% (-0.01%)
4% less funds holding
Funds holding: 71 → 68 (-3)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
41% less capital invested
Capital invested by funds: $115M → $68.3M (-$46.6M)
46% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$4.76M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.8M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.02M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$715K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$486K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$4.81M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$1.26M |
| 3 |
Millennium Management
New York
|
-$1.01M |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$909K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$768K |
PVLA Hedge Fund Activity: Q2 2022 in Review
68 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2022, worth a combined $68.3M — down 41% from $115M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PVLA and 12 opened new positions — a net loss of 3 holders — while 26 trimmed existing stakes and 14 added.
The largest buyer was Lynx1 Capital Management, adding an estimated $4.76M. The largest seller was Woodline Partners, exiting entirely with an estimated $4.81M sold.
- 68 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2022, down from 71 in Q1 2022.
- Funds reported $68.3M of Palvella Therapeutics stock for Q2 2022, down 41% quarter-over-quarter.
- 12 funds opened new Palvella Therapeutics positions in Q2 2022 and 15 closed out, a net change of -3 holders.
- The largest Palvella Therapeutics buyer in Q2 2022 was Lynx1 Capital Management, an estimated $4.76M added.
- The largest Palvella Therapeutics seller in Q2 2022 was Woodline Partners, an estimated $4.81M sold.
Based on aggregated 13F filings for Q2 2022.